Midatech Pharma Plc Price/Sales
Cos'è Price/Sales di Midatech Pharma Plc?
Price/Sales di Midatech Pharma Plc è 2.51
Qual è la definizione di Price/Sales?
Il rapporto prezzo / vendite è il prezzo delle azioni di una società rispetto ai suoi ricavi.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales di aziende nel Health Care settore su LSE rispetto a Midatech Pharma Plc
Cosa fa Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Aziende con price/sales simili a Midatech Pharma Plc
- Kingston ha Price/Sales di 2.51
- Cadila Healthcare ha Price/Sales di 2.51
- Aberdeen Emerging Markets Investment Co ha Price/Sales di 2.51
- Pantheon International Plc ha Price/Sales di 2.51
- BHP ha Price/Sales di 2.51
- Finjan ha Price/Sales di 2.51
- Midatech Pharma Plc ha Price/Sales di 2.51
- Bachem AG ha Price/Sales di 2.51
- Exasol AG ha Price/Sales di 2.51
- Tikkurila Oyj ha Price/Sales di 2.51
- Mirum Pharmaceuticals Inc ha Price/Sales di 2.51
- Mayur Uniquoters ha Price/Sales di 2.51
- 123869 ha Price/Sales di 2.51